ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Earnings and Valuation
This table compares ZyVersa Therapeutics and Rani Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ZyVersa Therapeutics | N/A | N/A | -$14.12 million | N/A | N/A |
| Rani Therapeutics | $2.72 million | 36.14 | -$30.59 million | ($1.38) | -1.43 |
ZyVersa Therapeutics has higher earnings, but lower revenue than Rani Therapeutics.
Institutional and Insider Ownership
Profitability
This table compares ZyVersa Therapeutics and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ZyVersa Therapeutics | N/A | N/A | N/A |
| Rani Therapeutics | N/A | -50.92% | -34.75% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for ZyVersa Therapeutics and Rani Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ZyVersa Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Rani Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
ZyVersa Therapeutics presently has a consensus price target of $2.50, indicating a potential upside of 2,083.41%. Rani Therapeutics has a consensus price target of $20.25, indicating a potential upside of 922.73%. Given ZyVersa Therapeutics’ higher probable upside, equities analysts plainly believe ZyVersa Therapeutics is more favorable than Rani Therapeutics.
Volatility & Risk
ZyVersa Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Summary
ZyVersa Therapeutics beats Rani Therapeutics on 5 of the 9 factors compared between the two stocks.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
